CN1874776A - 治疗慢性骨髓性白血病(cml)的4－苯胺基－3－喹啉腈 - Google Patents

治疗慢性骨髓性白血病(cml)的4－苯胺基－3－喹啉腈 Download PDF

Info

Publication number
CN1874776A
CN1874776A CNA2004800323110A CN200480032311A CN1874776A CN 1874776 A CN1874776 A CN 1874776A CN A2004800323110 A CNA2004800323110 A CN A2004800323110A CN 200480032311 A CN200480032311 A CN 200480032311A CN 1874776 A CN1874776 A CN 1874776A
Authority
CN
China
Prior art keywords
amino
methoxyl group
chloro
quinoline
methoxyphenyls
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800323110A
Other languages
English (en)
Chinese (zh)
Inventor
弗兰克·查尔斯·博舍立
珍妮弗·米谢勒·格拉斯
金·蒂莫西·阿恩特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34590192&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1874776(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CN1874776A publication Critical patent/CN1874776A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2004800323110A 2003-11-06 2004-11-03 治疗慢性骨髓性白血病(cml)的4－苯胺基－3－喹啉腈 Pending CN1874776A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51781903P 2003-11-06 2003-11-06
US60/517,819 2003-11-06

Publications (1)

Publication Number Publication Date
CN1874776A true CN1874776A (zh) 2006-12-06

Family

ID=34590192

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800323110A Pending CN1874776A (zh) 2003-11-06 2004-11-03 治疗慢性骨髓性白血病(cml)的4－苯胺基－3－喹啉腈

Country Status (18)

Country Link
US (2) US7417148B2 (enExample)
EP (1) EP1680119A1 (enExample)
JP (1) JP2007533655A (enExample)
KR (1) KR20060118461A (enExample)
CN (1) CN1874776A (enExample)
AU (1) AU2004289243B2 (enExample)
BR (1) BRPI0416289A (enExample)
CA (1) CA2543163A1 (enExample)
CO (1) CO5690608A2 (enExample)
CR (1) CR8350A (enExample)
EC (1) ECSP066548A (enExample)
IL (1) IL175424A0 (enExample)
MX (1) MXPA06004744A (enExample)
NO (1) NO20062255L (enExample)
RU (1) RU2006113691A (enExample)
SG (1) SG146681A1 (enExample)
WO (1) WO2005046693A1 (enExample)
ZA (1) ZA200603596B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004289243B2 (en) * 2003-11-06 2010-07-22 Wyeth Llc 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
JP5121706B2 (ja) * 2005-06-17 2013-01-16 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム Ｓｒｃキナーゼ阻害薬による溶骨性病変の阻害
BRPI0611977A2 (pt) * 2005-06-24 2010-10-13 Wyeth Corp uso de um composto
US20080119463A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
WO2008064004A2 (en) * 2006-11-16 2008-05-29 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
WO2008060283A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
CA2868899C (en) * 2007-06-01 2017-06-13 Wyeth Llc Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles having mutation in the bcrabl gene
WO2013187967A1 (en) 2012-06-15 2013-12-19 Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control
BR112014032346A2 (pt) 2012-06-26 2017-06-27 Del Mar Pharmaceuticals métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes
US9776970B2 (en) 2014-02-20 2017-10-03 Apotex Inc. Bosutinib forms and preparation methods thereof
SG11201705767PA (en) 2015-01-13 2017-08-30 Univ Kyoto Agent for preventing and/or treating amyotrophic lateral sclerosis
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
US12398355B2 (en) 2019-04-09 2025-08-26 Massachusetts Institute Of Technology Micro physiological model for neuronal and muscular diseases and disorders
WO2022053130A1 (en) 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US20040229880A1 (en) 2003-02-21 2004-11-18 Wyeth 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
AU2004289243B2 (en) * 2003-11-06 2010-07-22 Wyeth Llc 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)

Also Published As

Publication number Publication date
US20100029677A1 (en) 2010-02-04
ZA200603596B (en) 2009-12-30
AU2004289243B2 (en) 2010-07-22
NO20062255L (no) 2006-08-01
MXPA06004744A (es) 2006-07-05
RU2006113691A (ru) 2007-12-20
CR8350A (es) 2006-10-06
US20050101780A1 (en) 2005-05-12
WO2005046693A1 (en) 2005-05-26
ECSP066548A (es) 2006-10-17
AU2004289243A1 (en) 2005-05-26
JP2007533655A (ja) 2007-11-22
CO5690608A2 (es) 2006-10-31
IL175424A0 (en) 2008-04-13
CA2543163A1 (en) 2005-05-26
SG146681A1 (en) 2008-10-30
KR20060118461A (ko) 2006-11-23
BRPI0416289A (pt) 2007-01-23
EP1680119A1 (en) 2006-07-19
US7417148B2 (en) 2008-08-26
US7919625B2 (en) 2011-04-05

Similar Documents

Publication Publication Date Title
US7919625B2 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
CN1976704A (zh) 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途
CN1921864A (zh) 使用TGF－β抑制剂治疗神经胶质瘤
CN1370080A (zh) 用于治疗或抑制结肠息肉和结肠直肠癌的含有nsaid和efgr激酶抑制剂的组合物
CN1921885A (zh) Sr蛋白质的磷酸化控制方法以及以sr蛋白质活性控制剂为有效成分的抗病毒剂
CN1976906A (zh) 用作parp抑制剂的取代2－烷基喹唑啉酮衍生物
CN1960725A (zh) 用于抑制血管发生的四环咔啉衍生物
CN1529602A (zh) N-苯基-2-嘧啶胺衍生物在抗肥大细胞基的疾病如变应性疾病中的用途
EP4548977A2 (en) Novel isoquinolines as protein degraders, e7 degraders, antivirals, tumor therapeutics and immune suppressives
CN1360502A (zh) 多巴胺d3受体配体在生产肾功能紊乱治疗药物中的应用
JP2016074700A (ja) ４−アミノキノリン−３−カルボニトリルを使用するイマチニブ耐性白血病の処置
JP2024537139A (ja) ＫＲＡＳ Ｇ１２Ｄ阻害剤とＰＩ３Ｋａ阻害剤との組み合わせ及び関連する治療方法
CN102274230A (zh) Kit突变形式的抑制剂
CN1750824A (zh) 用于治疗局部缺血性损伤的4－[(2,4－二氯－5－甲氧苯基)氨基]－6－烷氧基－3－氰基喹琳类
JP2025507382A (ja) ｃＧＡＳ阻害物質およびその使用法
CN1852737A (zh) 组蛋白脱乙酰酶抑制剂与死亡受体配体的组合
EP4074314A1 (en) Isoquinoline derivatives for use as antiviral and antitumour agents
WO2024083802A1 (en) Isoquinoline derivatives as protein degraders, e7 degraders, antivirals, tumor therapeutics and immune suppressives
KR20220142828A (ko) E7 분해제
JP2008110935A (ja) ２−フェニルベンゾイミダゾール誘導体を有効成分とするｓｔａｔ６活性化阻害剤
WO2005047259A1 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
CN1711088A (zh) 治疗癌症的方法及相关方法
JP2005145928A (ja) ３−キノリン−２（１ｈ）−イリデンインドリン−２−オン誘導体を有効成分とする医薬組成物
WO2025160221A1 (en) Myc amplification drives resistance to pan-ras inhibitors in pancreatic cancer
CN101035535A (zh) 4－( 4－甲基哌嗪－1－基甲基)－N－[4－甲基－3－(4－(吡啶－3－基 )嘧啶－2－基氨基)苯基]－苯甲酰胺用于抑制酪氨酸激酶受体c－fms的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication